Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 11/20 | 0.66 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520828 | 0.89 | ALDH1A1 (0.68) | ALDH1A1LMNAMAPTSIRT6TDP1 | |
| SCHEMBL12862152 | 0.89 | ALDH1A1 (0.68) | ALDH1A1LMNAMAPTSIRT6TDP1 | |
| SCHEMBL12312147 | 0.88 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTSIRT6TDP1 | |
| SCHEMBL12312101 | 0.88 | ALDH1A1 (0.67) | ALDH1A1LMNAMAPTSIRT6HTR6 | |
| SCHEMBL517280 | 0.86 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTSIRT6TDP1 | |
| SCHEMBL517279 | 0.86 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTSIRT6TDP1 | |
| SCHEMBL22955203 | 0.86 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPTSIRT6TDP1 | |
| SCHEMBL311272 | 0.85 | ALDH1A1 (0.73) | ALDH1A1LMNAMAPTSIRT6TDP1 | |
| SCHEMBL520526 | 0.83 | SIRT6 (0.71) | ALDH1A1LMNAMAPTSIRT6HTR6 | |
| SCHEMBL23654833 | 0.83 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTSIRT6HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111406-A2 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | ALDH1A1 238/4885LMNA 2130/4885MAPT 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.